Publications! See pages 23-24 of Annual Information Form, also copied below.

We already knew about the first one below. But one more has been accepted with revision and two more have been submitted, including the long awaited BETonMACE trial design and rationale paper!

I am very impressed by the volume of research that Resverlogix and collaborators have been publishing over the years. So much informative published on apabetalone research.

• "A manuscript titled  “Apabetalone  (RVX-208)  reduces  vascular  inflammation in  vitro  and  in CVD  patients  by  a  BET-dependent epigenetic  mechanism” was  recently  accepted  by  Clinical Epigenetics  (In  Press).  This  publication  highlights  the  effects  of apabetalone  treatment  on markers  of  vascular  inflammation  and  cellular  adhesion  in  vitro  and  in  clinical  plasma  samples,  as well  as  showing  a  reduction of  monocyte  adhesion  to  endothelial cells  in  cell models,  with  additional  data  supporting  the  BET dependent  nature  of  these  processes.
• Currently,  an  additional  manuscript  has  been  accepted  with  revisions  to  the  Journal of  Translational Medicine,  titled  “Epigenetic modulation by  apabetalone  counters  cytokine  driven  acute  phase  response  in  vitro,  in mice  and  in cardiovascular  disease patients”. This  work  compiles  all  findings  to  date  regarding  apabetalone’s  effects  on the  acute  phase  response,  related  targets and  pathways.   
• A manuscript has  been  submitted  to  the American  Heart Journal  titled  “Effect of  selective BET  protein inhibitor  apabetalone  on cardiovascular  outcomes  in  patients  with  acute  coronary  syndrome  and  diabetes:  Rationale,  design,  and  baseline characteristics  of  the  BETonMACE trial”  outlining  details  of  BETonMACE  study  design  and  patient  characteristics  collected  at enrollment. 
• We have submitted  a  manuscript titled  “Apabetalone  Lowers  Serum  Alkaline  Phosphatase  and  Improves  Cardiovascular  Risk  in Patients  with  Cardiovascular  Disease”,  led  and  written  in  collaboration  with  clinical  experts  in  the  area  ALP  and  CKD,  This publication has  been  re-submitted  with  requested  edits  to  Atheroslcerosis.  Data  contained  in  this  manuscript  highlights  the  role of  ALP  in cardiovascular  risk,  and  the  benefits  of  apabetalone  induced  reduction of  ALP  in reducing  cardiovascular  risk  in treated  CVD  patients."